

CLAIMS

1. A combination comprising a therapeutically non-effective dose of paroxetine or physiologically acceptable salts or solvates thereof and a therapeutically non-effective dose of 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically acceptable salts or solvates thereof.
2. A combination as claimed in claim 1 wherein the paroxetine is present as its hydrochloride hemihydrate salt and 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide is present as its methansulphonate salt.
3. A combination as claimed in claim 1 or claim 2 comprising paroxetine or physiologically salts or solvates thereof in an amount from 1 to 10 mg (measured as the free base).
4. A combination as claimed in any claims 1 to 3 comprising paroxetine or physiologically salts or solvates thereof in an amount from 3.5 to 7.5 mg (measured as the free base).
5. A combination as claimed in any claims 1 to 4 comprising 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid[1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically salts or solvates thereof in an amount from 0.5 to 5 mg (measured as the free base).
6. A combination as claimed in any claims 1 to 5 comprising 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid 1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically salts or solvates thereof in an amount from 1 to 3 mg (measured as the free base).
7. A combination as claimed in any claims 1 to 6 comprising 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically salts or solvates thereof in an amount from 1.5 to 2.5 mg (measured as the free base).

8. A combination as claimed in any claims 1 to 7 comprising paroxetine or physiologically salts or solvates thereof in an amount from 1 to 10 mg (measured as the free base) and 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically salts or solvates thereof in an amount from 0.5 to 5 mg (measured as the free base);
9. A combination as claimed in any claims 1 to 8 comprising paroxetine or physiologically salts or solvates thereof in an amount from 1 to 10 mg (measured as the free base) and 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically salts or solvates thereof in an amount from 1 to 3 mg (measured as the free base).
10. A combination as claimed in any claims 1 to 9 comprising paroxetine or physiologically salts or solvates thereof in an amount from 1 to 10 mg (measured as the free base) and 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically salts or solvates thereof in an amount from 1.5 to 2.5 mg (measured as the free base).
11. A combination as claimed in any claims 1 to 10 comprising paroxetine or physiologically salts or solvates thereof in an amount from 3.5 to 7.5 mg (measured as the free base) and 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically salts or solvates thereof in an amount from 0.5 to 5 mg (measured as the free base).
12. A combination as claimed in any claims 1 to 11 comprising paroxetine or physiologically salts or solvates thereof in an amount from 3.5 to 7.5 mg (measured as the free base) and 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically salts or solvates thereof in an amount from 1 to 3 mg (measured as the free base).

13. A combination as claimed in any claims 1 to 12 comprising paroxetine or physiologically salts or solvates thereof in an amount from 3.5 to 7.5 mg (measured as the free base) and 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methanamide or pharmaceutically salts or solvates thereof in an amount from 1.5 to 2.5 mg (measured as the free base).
14. A combination according to any of claims 1 to 13 for use in the treatment and or prophylaxis of depression and /or anxiety.
15. A method for the treatment and/or prophylaxis of depression and/or anxiety in a mammal including a human, which comprises treating said animal with a therapeutically effective amount of a combination as claimed in any of claims 1 to 13.
16. A pharmaceutical formulation comprising a combination according to any of the claims 1 to 13 together with one or more pharmaceutically acceptable carriers or excipients.
17. The use of a combination according to any claims 1 to 13 in the manufacture of a therapeutically effective medicament for simultaneous or sequential administration for the treatment and/or prophylaxis of depression and /or anxiety.